<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21720" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fexofenadine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Craun</surname>
            <given-names>Kari L.</given-names>
          </name>
          <aff>Mclaren Oakland Hosp, MS College OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schury</surname>
            <given-names>Mark P.</given-names>
          </name>
          <aff>McLaren Oakland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kari Craun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Schury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21720.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fexofenadine, a second-generation antihistamine, is a metabolite of terfenadine.&#x000a0;The US Food and Drug Administration (FDA) approved&#x000a0;fexofenadine to treat seasonal allergic rhinitis and chronic idiopathic urticaria. Fexofenadine is approved for use in both children and adults. Children may be eligible for treatment starting at 6 months or older, depending on the specific indications.</p>
        <p>Fexofenadine acts by selectively antagonizing H1 receptors on cell surfaces across various organ systems, thereby affecting inflammatory mediators. As a&#x000a0;second-generation antihistamine, fexofenadine exhibits reduced affinity for cholinergic and &#x003b1;-adrenergic receptors, which results in minimal anticholinergic effects. This drug also demonstrates high specificity for H1 receptors and lacks anticholinergic activity. This activity provides information about fexofenadine, including its indications, mechanism of action, administration, adverse event profile, contraindications, and other critical factors such as monitoring, drug interactions, and clinical toxicology. This activity also aims to&#x000a0;enhance the competence of&#x000a0;interprofessional&#x000a0;healthcare providers involved in treating patients with allergic rhinitis and chronic urticaria by providing them with the necessary skills to improve patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for fexofenadine therapy in patients with allergic rhinitis and chronic urticaria.</p></list-item><list-item><p>Implement evidence-based guidelines for dosage and administration of fexofenadine in pediatric and adult populations based on patient age, severity of symptoms, and comorbidities.</p></list-item><list-item><p>Assess patient response to fexofenadine therapy through regular monitoring of symptom improvement and adverse effects.</p></list-item><list-item><p>Collaborate with other healthcare professionals to&#x000a0;manage allergic rhinitis and chronic urticaria and comprehensively address patient concerns to&#x000a0;optimize fexofenadine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21720&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21720">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21720.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fexofenadine, a second-generation antihistamine, is a metabolite of terfenadine.&#x000a0;The US Food and Drug Administration (FDA) approved&#x000a0;fexofenadine to treat seasonal allergic rhinitis and chronic idiopathic urticaria. Fexofenadine is approved for use in both children and adults. Depending on the specific indications, children may be eligible for treatment starting at 6 months or older.<xref ref-type="bibr" rid="article-21720.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>Seasonal allergic rhinitis:&#x000a0;</bold>Seasonal allergic rhinitis is characterized by nasal itching, sneezing, rhinorrhea, and nasal congestion. However, antihistamines are typically less effective in relieving nasal congestion. Triggers for seasonal or perennial allergic rhinitis may include grass, pollens, dust, pet dander, and mold.<xref ref-type="bibr" rid="article-21720.r2">[2]</xref> In a double-blind, placebo-controlled, randomized trial, fexofenadine demonstrated comparable safety and efficacy to loratadine. Notably, fexofenadine was found to be effective in alleviating ocular and nasal congestion symptoms.<xref ref-type="bibr" rid="article-21720.r3">[3]</xref>&#x000a0;According&#x000a0;to the American Academy of Allergy, Asthma, &#x00026; Immunology (AAAAI), clinicians may consider supplementing treatment with pseudoephedrine if allergic rhinitis and nasal congestion persist despite oral antihistamine use. The fixed-dose combination of fexofenadine and pseudoephedrine has proven to be beneficial.<xref ref-type="bibr" rid="article-21720.r4">[4]</xref></p>
        <p><bold>Chronic idiopathic urticaria:&#x000a0;</bold>Chronic idiopathic urticaria is caused by spontaneous mast cell degranulation.<xref ref-type="bibr" rid="article-21720.r2">[2]</xref>&#x000a0;Symptomatic triggers include water, sweat, sun, cold, or pressure, including dermatographism and urticarial rash. In addition, angiotensin-converting enzyme (ACE) inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs) may induce chronic urticaria.<xref ref-type="bibr" rid="article-21720.r5">[5]</xref> Fexofenadine is also effective in treating cholinergic urticaria.<xref ref-type="bibr" rid="article-21720.r6">[6]</xref>&#x000a0;According to AAAAI and the American College of Allergy, Asthma &#x00026; Immunology (ACAAI), second-generation antihistamines, such as fexofenadine, are&#x000a0;considered&#x000a0;safe and effective for managing cholinergic urticaria.<xref ref-type="bibr" rid="article-21720.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p><bold>Eczema (add-on treatment):&#x000a0;</bold>A systematic review evaluated the effectiveness of oral H1 antihistamines as supplementary therapy alongside topical treatments for eczema. Despite varying evidence regarding their effectiveness, the review indicated that fexofenadine might&#x000a0;relieve&#x000a0;pruritus. However, challenges arose from limitations in the quality of evidence due to suboptimal study designs and imprecise outcomes, hindering the ability to reach definitive conclusions.<xref ref-type="bibr" rid="article-21720.r8">[8]</xref></p>
      </sec>
      <sec id="article-21720.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action of fexofenadine is to selectively antagonize H1 receptors on cell surfaces across various organ systems, thereby affecting inflammatory mediators.<xref ref-type="bibr" rid="article-21720.r9">[9]</xref><xref ref-type="bibr" rid="article-21720.r10">[10]</xref>&#x000a0;Compared to other first-generation antihistamines, fexofenadine crosses the blood-brain barrier minimally and does not cause drowsiness. As a&#x000a0;second-generation antihistamine, fexofenadine exhibits reduced affinity for cholinergic and &#x003b1;-adrenergic receptors, which results in minimal anticholinergic effects.</p>
        <p>In a study, second-generation antihistamines such as desloratadine and loratadine showed anticholinergic activity, whereas fexofenadine exhibited no anticholinergic effects and displayed high specificity for H1 receptors. As a result, fexofenadine is recognized as one of the least sedating second-generation antihistamines.<xref ref-type="bibr" rid="article-21720.r11">[11]</xref>&#x000a0;Fexofenadine can also inhibit other mechanisms such as mast cell, basophilic histamine, and inflammatory cell release.<xref ref-type="bibr" rid="article-21720.r12">[12]</xref>&#x000a0;Prolonged use of fexofenadine does not cause tachyphylaxis.<xref ref-type="bibr" rid="article-21720.r13">[13]</xref> Meta-analysis findings indicate that the antihistamine effects of fexofenadine, as measured by the histamine-induced wheal and flare inhibition rate, are significantly superior to placebo and comparable to other second-generation antihistamines.<xref ref-type="bibr" rid="article-21720.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Fexofenadine demonstrates rapid absorption, reaching peak plasma concentrations within 1 hour after oral administration for the suspension and 1.5 hours for the tablet. Maximum histamine inhibition occurs approximately 1 to 2 hours post-administration. As a long-acting antihistamine, fexofenadine is recommended for daily use.<xref ref-type="bibr" rid="article-21720.r15">[15]</xref></p>
        <p><bold>Distribution:</bold> Fexofenadine exhibits approximately 60% to 70% plasma protein binding. The drug predominantly binds to albumin and alpha-1 acid glycoprotein. Notably, fexofenadine does not occupy receptors in the central nervous system.<xref ref-type="bibr" rid="article-21720.r16">[16]</xref></p>
        <p><bold>Metabolism:</bold> Fexofenadine undergoes minimal hepatic metabolism. The&#x000a0;metabolism and transportation of fexofenadine in the body rely significantly on organic anion transporting polypeptides (OATP2B1) and permeability glycoprotein (P-gp). Notably, P-gp facilitates both intestinal secretion and systemic disposition of fexofenadine.<xref ref-type="bibr" rid="article-21720.r17">[17]</xref></p>
        <p><bold>Elimination: </bold>In healthy volunteers, the mean elimination half-life of fexofenadine is approximately 14.4 hours when administered at a dosage of 60 mg twice daily. Fexofenadine is primarily excreted in feces via biliary excretion, accounting for 80% of elimination. However, the half-life of fexofenadine may be significantly prolonged in patients with renal disease.<xref ref-type="bibr" rid="article-21720.r18">[18]</xref></p>
      </sec>
      <sec id="article-21720.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Fexofenadine&#x000a0;is available in various&#x000a0;formulations for oral administration, including tablets, oral suspension (syrup), and orally disintegrating tablets (ODTs). In addition, a combination product that contains both fexofenadine and pseudoephedrine is available.<xref ref-type="bibr" rid="article-21720.r19">[19]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Although fexofenadine is suitable for both adults and children, the dosage for children is lower&#x000a0;than&#x000a0;that for adults (up to 60 mg versus 180 mg PO daily). ODT tablets are branded and should be administered by placing the tablet on the tongue, allowing it to dissolve with or without water, and swallowing without chewing.&#x000a0;Notably, it&#x000a0;is recommended that patients should take the medication&#x000a0;before having any food or drinks. ODT tablets are&#x000a0;commonly prescribed for pediatric patients, with a dosage of 30 mg PO BID for children aged 6 to 12 for managing seasonal allergic rhinitis and chronic urticaria.<xref ref-type="bibr" rid="article-21720.r20">[20]</xref>&#x000a0;</p>
        <p>A fixed-dose combination containing 60 mg of fexofenadine and 120 mg of pseudoephedrine, formulated for treating seasonal allergic rhinitis with nasal congestion, is administered to patients every 12 hours. Another fixed-dose combination containing 180 mg of fexofenadine and 240 mg of pseudoephedrine is administered daily. The seasonal allergic rhinitis and chronic urticaria dosage is 60 or 180 mg PO daily.<xref ref-type="bibr" rid="article-21720.r7">[7]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The manufacturer of the product has not provided recommendations for dosage adjustment based on hepatic function.</p>
        <p><bold>Renal impairment: </bold>The recommendations for individuals with a creatinine clearance below 80 mL/min are provided below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: Adults should take 60 mg of fexofenadine&#x000a0;PO daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric patients: Dosing for pediatric patients with renal impairment varies by age, as mentioned below.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Children aged&#x000a0;6 to 24 months: 15 mg PO daily.</p>
              </list-item>
              <list-item>
                <p>Children aged 2 to 12: 30 mg PO daily.</p>
              </list-item>
              <list-item>
                <p>Children aged 12 or older: 60 mg PO daily.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>End-stage renal disease (ESRD) decreases nonrenal transporter function, resulting in a 63% decrease in clearance and a 2.8-fold increase in area under the curve (AUC) for fexofenadine. Therefore, dose reduction is necessary in patients with ESRD.<xref ref-type="bibr" rid="article-21720.r21">[21]</xref></p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold> Fexofenadine (formerly categorized as an FDA pregnancy category C drug) is typically avoided during pregnancy, with other antihistamines supported by more extensive data being preferred.<xref ref-type="bibr" rid="article-21720.r22">[22]</xref>&#x000a0;However, a large nationwide cohort study found no apparent association between fexofenadine use during pregnancy and the risk of congenital malformations or stillbirth.<xref ref-type="bibr" rid="article-21720.r23">[23]</xref>&#x000a0;According to the American College of Obstetricians&#x000a0;and&#x000a0;Gynecologists (ACOG) and the ACAAI guidelines, a first-generation antihistamine, such as chlorpheniramine, is preferred during pregnancy. If a patient is intolerant to chlorpheniramine, alternatives such as loratadine, desloratadine, and cetirizine are considered safe to use during pregnancy after the first trimester.<xref ref-type="bibr" rid="article-21720.r24">[24]</xref><xref ref-type="bibr" rid="article-21720.r25">[25]</xref><xref ref-type="bibr" rid="article-21720.r26">[26]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Fexofenadine, combined with pseudoephedrine, may reduce milk production. While breastfeeding, monitoring the infant for signs of irritability and jitteriness is important.<xref ref-type="bibr" rid="article-21720.r27">[27]</xref><xref ref-type="bibr" rid="article-21720.r28">[28]</xref></p>
        <p><bold>Pediatrics patients:</bold> Fexofenadine dosages vary depending on age and the specific condition of the patient being treated.</p>
        <list list-type="bullet">
          <list-item>
            <p>Seasonal allergic rhinitis: The specific dosages for this condition&#x000a0;are mentioned below.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Children aged &#x0003c;2:&#x000a0;Not approved for use</p>
              </list-item>
              <list-item>
                <p>Children aged 2 to 12: 30 mg PO BID</p>
              </list-item>
              <list-item>
                <p>Children aged 12 or older: 60 mg PO BID or 180 mg PO daily</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic urticaria: The specific dosages for this condition are mentioned below.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Infants aged &#x0003c;6 months:&#x000a0;Not approved for use</p>
              </list-item>
              <list-item>
                <p>Children aged 6 to 24 months: 15 mg PO BID</p>
              </list-item>
              <list-item>
                <p>Children aged 2 to 12: 30 mg PO BID</p>
              </list-item>
              <list-item>
                <p>Children aged 12 or older: 60 or 180 mg PO daily</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold>Older patients:&#x000a0;</bold>Fexofenadine is frequently prescribed as an antihistamine for managing allergic rhinitis in older individuals due to its favorable safety profile, which is attributed to its limited penetration of the blood-brain barrier. Furthermore, second-generation antihistamines are associated with fewer anticholinergic adverse effects compared to first-generation antihistamines.<xref ref-type="bibr" rid="article-21720.r29">[29]</xref></p>
      </sec>
      <sec id="article-21720.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common dose-dependent adverse drug reactions associated with fexofenadine include drowsiness, fatigue, and dry mouth.<xref ref-type="bibr" rid="article-21720.r30">[30]</xref>&#x000a0;In addition, post-marketing surveillance has reported rare occurrences of Stevens-Johnson syndrome or toxic epidermal necrolysis induced by fexofenadine.<xref ref-type="bibr" rid="article-21720.r31">[31]</xref></p>
        <p>Adverse effects reported in a meta-analysis of randomized controlled trials include <xref ref-type="bibr" rid="article-21720.r14">[14]</xref>&#x000a0;headache, epistaxis, sinusitis, rash, abdominal pain, diarrhea, leukopenia, back pain, weakness, sedation or drowsiness, and dry mouth.<xref ref-type="bibr" rid="article-21720.r30">[30]</xref></p>
        <p>
<bold>Drug-Drug and Drug-Food Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fexofenadine, regardless of the route of administration, exhibits decreased bioavailability when taken with grapefruit, apple, or orange juice. This reduced bioavailability occurs due to the inhibition of the P-gp transporter. Patients should be advised to&#x000a0;administer fexofenadine and any of these juices at least 4 hours apart.<xref ref-type="bibr" rid="article-21720.r32">[32]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Green tea has been found to reduce the bioavailability of fexofenadine by inhibiting the OATP1A2-mediated intestinal absorption of fexofenadine, thereby decreasing its efficacy.<xref ref-type="bibr" rid="article-21720.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Betahistine, acting as an antagonist of histamine H3 receptors and a weak agonist of H1 receptors, can decrease the therapeutic potential of fexofenadine.<xref ref-type="bibr" rid="article-21720.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pilolisant is a histamine-3 receptor antagonist and inverse agonist approved for narcolepsy. However, concurrent use of antihistamines is not recommended.<xref ref-type="bibr" rid="article-21720.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Apalutamide decreases the AUC of fexofenadine by 30% when administered&#x000a0;concurrently with transporter&#x000a0;substrates for P-gp, such as fexofenadine, which may result in a loss of efficacy for fexofenadine.<xref ref-type="bibr" rid="article-21720.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Case reports have shown instances where fexofenadine yielded false-positive results for tramadol in urine drug screenings designed for substance use disorders. Therefore, caution is advised when interpreting positive tramadol results in urine tests for individuals taking fexofenadine. Further research is required to gain a comprehensive understanding of this interaction.<xref ref-type="bibr" rid="article-21720.r37">[37]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21720.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Hypersensitivity to fexofenadine or any of its components is the sole true contraindication to its use. Although hepatic involvement in the clearance of this medication is minimal, it is safe for patients with liver pathology. However, caution is necessary when treating patients with renal disease, and as mentioned above, adherence to renal dosing guidelines is essential in these cases.<xref ref-type="bibr" rid="article-21720.r38">[38]</xref>&#x000a0;</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>No significant interaction is evidenced between fexofenadine and concomitant alcohol or food consumption. However, fexofenadine's bioavailability decreases when consumed with grapefruit, apple, or orange juices.<xref ref-type="bibr" rid="article-21720.r39">[39]</xref>&#x000a0;In&#x000a0;animal studies, fexofenadine has been associated with low birth weight and is categorized as an FDA category C drug during pregnancy. Alternative options for relieving allergic rhinitis symptoms include loratadine and cetirizine.<xref ref-type="bibr" rid="article-21720.r40">[40]</xref>&#x000a0;ODTs of fexofenadine&#x000a0;may contain phenylalanine as an excipient, necessitating caution in patients with phenylketonuria.<xref ref-type="bibr" rid="article-21720.r41">[41]</xref></p>
      </sec>
      <sec id="article-21720.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring fexofenadine involves evaluating for any improvement or worsening of symptoms with use. Due to its historical association with cardiotoxicity in terfenadine, patients with underlying cardiac conditions may require periodic electrocardiogram (ECG) monitoring to detect any potential QT prolongation or arrhythmias.<xref ref-type="bibr" rid="article-21720.r42">[42]</xref></p>
        <p>A study comparing fexofenadine and levocetirizine for chronic urticaria revealed that dosage twice the recommended dose demonstrated improved urticarial symptoms without increasing adverse effects. The most frequently reported adverse effects were fatigue and drowsiness, occurring at similar rates in patients taking the recommended dose compared to those taking the higher dose. In addition, the study referenced a European study where the dosage was quadrupled, resulting in similar adverse effects.<xref ref-type="bibr" rid="article-21720.r43">[43]</xref>&#x000a0;</p>
        <p>The Rhinitis Control Assessment Test is a valuable tool for&#x000a0;clinicians to assess the effectiveness of treatments in managing allergic rhinitis.<xref ref-type="bibr" rid="article-21720.r4">[4]</xref>&#x000a0;In addition, monitoring the quality of life can be achieved through the use of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), while the impact of fexofenadine therapy on reducing urticaria symptoms can be evaluated using the Urticaria Activity Score (UAS7).<xref ref-type="bibr" rid="article-21720.r44">[44]</xref></p>
      </sec>
      <sec id="article-21720.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Fexofenadine, a metabolite of terfenadine, is associated with cardiotoxic effects. Terfenadine, when taken in high doses or with certain medications like ketoconazole, blocks cardiac potassium channels, resulting in prolonged QT intervals, which can lead to fatal arrhythmias. Following FDA guidelines, fexofenadine has replaced terfenadine in the United States due to its lack of potassium channel blockade. Multiple studies have confirmed that fexofenadine does not induce arrhythmias or significantly prolong QT intervals.<xref ref-type="bibr" rid="article-21720.r42">[42]</xref>&#x000a0;</p>
        <p>Despite the findings of these studies, some case reports have suggested a potential association between fexofenadine and QT-interval elongation and ventricular arrhythmia. Concurrent use of fexofenadine with hepatic CYP3A4 blockers, such as erythromycin and ketoconazole, may elevate blood concentration levels. In contrast, combined use with drugs such as rifampin and troglitazone can decrease concentration levels. These effects are likely attributed to interactions between these compounds and the P-gp transporter, which facilitates the removal of fexofenadine from the bloodstream.<xref ref-type="bibr" rid="article-21720.r45">[45]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No specific antidote exists for fexofenadine overdose. Therefore, treatment in the event of an overdose primarily involves supportive measures. If an overdose is suspected, it is recommended to contact the poison control center or consult with a medical toxicologist, particularly if exposure to multiple substances is suspected.<xref ref-type="bibr" rid="article-21720.r46">[46]</xref></p>
      </sec>
      <sec id="article-21720.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fexofenadine is a commonly prescribed medication for seasonal allergic rhinitis and chronic urticaria. In addition, it is important to exercise caution when initiating any new medication without a prescription. Patients should engage in discussions with their primary care clinicians and pharmacists regarding fexofenadine to understand potential adverse effects, recommended dosing, and potential interactions with commonly consumed items such as fruit juices. Clinicians should also ensure that patients receive the appropriate adjusted dosage of fexofenadine. Immunologists should be consulted for cases of refractory urticaria or allergic rhinitis. Nurses should verify the dosage of fexofenadine at each visit and periodically reassess patients' conditions. Pharmacists should conduct thorough checks for drug interactions and perform medication reconciliation while counseling patients. In the event of fexofenadine overdose, critical care clinicians and medical toxicologists should be consulted.</p>
        <p>If the overdose is determined to be intentional, the patient should be promptly referred to a psychiatrist for further evaluation and management. Collaborative efforts and coordination among the interprofessional healthcare team, comprising clinicians, specialists such as immunologists, nurses, and pharmacists, are critical in improving patient outcomes related to fexofenadine therapy. As advocated by the European Academy of Allergy and Clinical Immunology, integrated care involving clinicians, specialists, nurses, dietitians, psychologists, and pharmacists can significantly enhance patient-centered care for allergic disorders in community settings.<xref ref-type="bibr" rid="article-21720.r47">[47]</xref></p>
      </sec>
      <sec id="article-21720.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21720&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21720">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21720/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21720">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21720.s11">
        <title>References</title>
        <ref id="article-21720.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devillier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Faisy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2008</year>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-30</page-range>
            <pub-id pub-id-type="pmid">18336052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randall</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Antihistamines and allergy.</article-title>
            <source>Aust Prescr</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>41</fpage>
            <page-range>41-45</page-range>
            <pub-id pub-id-type="pmid">29670310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Cauwenberge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Juniper</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>891</fpage>
            <page-range>891-9</page-range>
            <pub-id pub-id-type="pmid">10848909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Amrol</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dinakar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>DES</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <collab>Chief Editor(s):</collab>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <collab>Joint Task Force on Practice Parameters:</collab>
              <name>
                <surname>Dinakar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <collab>Workgroup Contributors:</collab>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Amrol</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>DES</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Rhinitis 2020: A&#x000a0;practice parameter update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>146</volume>
            <issue>4</issue>
            <fpage>721</fpage>
            <page-range>721-767</page-range>
            <pub-id pub-id-type="pmid">32707227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansotegui</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Gonzalez-Diaz</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Morais-Almeida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murrieta-Aguttes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez Borges</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2022</year>
            <month>May</month>
            <day>13</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">35562767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iijima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kojo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hiragun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Case of cholinergic urticaria accompanied by anaphylaxis.</article-title>
            <source>J Dermatol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1291</fpage>
            <page-range>1291-1294</page-range>
            <pub-id pub-id-type="pmid">28665007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dreyfus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weldon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of acute and chronic urticaria: 2014 update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2014</year>
            <month>May</month>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>1270</fpage>
            <page-range>1270-7</page-range>
            <pub-id pub-id-type="pmid">24766875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matterne</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hmer</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weisshaar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jupiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Apfelbacher</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>22</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD012167</fpage>
            <pub-id pub-id-type="pmid">30666626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahatme</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dakhale</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Tadke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiware</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dudhgaonkar</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wankhede</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>649</fpage>
            <page-range>649-653</page-range>
            <pub-id pub-id-type="pmid">28066101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawauchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yanai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Itahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okubo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>08</day>
            <volume>20</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30626077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orzechowski</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Currie</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Valancius</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2005</year>
            <month>Jan</month>
            <day>04</day>
            <volume>506</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-64</page-range>
            <pub-id pub-id-type="pmid">15627436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Blaiss</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence.</article-title>
            <source>World Allergy Organ J</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>47</fpage>
            <page-range>47-53</page-range>
            <pub-id pub-id-type="pmid">23268457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Van Bever</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lucio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis.</article-title>
            <source>Allergy Asthma Clin Immunol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>02</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <pub-id pub-id-type="pmid">34727966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2019</year>
            <month>Nov</month>
            <day>29</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">31783781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-21</page-range>
            <pub-id pub-id-type="pmid">10730552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>El-Kattan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fenner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kempshall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lunn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stupple</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Speed</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.</article-title>
            <source>Xenobiotica</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-27</page-range>
            <pub-id pub-id-type="pmid">21970687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akamine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on the clinical pharmacokinetics of fexofenadine enantiomers.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>429</fpage>
            <page-range>429-434</page-range>
            <pub-id pub-id-type="pmid">29635947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Khier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fabre</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.</article-title>
            <source>J Pharmacokinet Pharmacodyn</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-95</page-range>
            <pub-id pub-id-type="pmid">24633780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansfield</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2006</year>
            <month>May</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>941</fpage>
            <page-range>941-51</page-range>
            <pub-id pub-id-type="pmid">16634716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Scheinmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rosado Pinto</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bachert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hedlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wahn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Ruuth</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-60</page-range>
            <pub-id pub-id-type="pmid">15209959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nolin</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Frye</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sadr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Naud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Pichette</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>ESRD impairs nonrenal clearance of fexofenadine but not midazolam.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>2269</fpage>
            <page-range>2269-76</page-range>
            <pub-id pub-id-type="pmid">19696225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murase</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>401.e1</fpage>
            <page-range>401.e1-14; quiz 415</page-range>
            <pub-id pub-id-type="pmid">24528911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.</article-title>
            <source>JAMA Pediatr</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>174</volume>
            <issue>8</issue>
            <fpage>e201316</fpage>
            <pub-id pub-id-type="pmid">32478810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preetha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mohankar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of antihistamines used during pregnancy.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-8</page-range>
            <pub-id pub-id-type="pmid">22629082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Leech</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Till</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>AT</given-names>
              </name>
              <collab>British Society for Allergy and Clinical Immunology</collab>
            </person-group>
            <article-title>BSACI guideline for the management of chronic urticaria and angioedema.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-65</page-range>
            <pub-id pub-id-type="pmid">25711134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2020</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>1598</fpage>
            <page-range>1598-1605</page-range>
            <pub-id pub-id-type="pmid">32142963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <chapter-title>Fexofenadine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">29999736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Murase</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>417.e1</fpage>
            <page-range>417.e1-10; quiz 427</page-range>
            <pub-id pub-id-type="pmid">24528912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Management of Allergic Rhinitis in the Elderly.</article-title>
            <source>Drugs Aging</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-28</page-range>
            <pub-id pub-id-type="pmid">27913982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Compalati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baena-Cagnani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Penagos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badellino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Braido</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Baena-Cagnani</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2011</year>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">21969990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancano</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS)<sup>1,2</sup>; Ivermectin-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption.</article-title>
            <source>Hosp Pharm</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>220</fpage>
            <page-range>220-222</page-range>
            <pub-id pub-id-type="pmid">30038437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Fruit juice inhibition of uptake transport: a new type of food-drug interaction.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>645</fpage>
            <page-range>645-55</page-range>
            <pub-id pub-id-type="pmid">21039758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Taudte</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Hoier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fromm</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Shimomura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>3</issue>
            <fpage>627</fpage>
            <page-range>627-634</page-range>
            <pub-id pub-id-type="pmid">35678032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Mizio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marcian&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palleria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muraca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rania</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roberti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spaziano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Piscopo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciconte</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Di Nunno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Sarro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiarella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gallelli</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2021</year>
            <month>Dec</month>
            <day>08</day>
            <volume>18</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">34948545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarfraz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okuampa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kakazu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.</article-title>
            <source>Health Psychol Res</source>
            <year>2022</year>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>34222</fpage>
            <pub-id pub-id-type="pmid">35774905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duran</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Carles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bulat</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hellemans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mitselos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>1135</fpage>
            <page-range>1135-1148</page-range>
            <pub-id pub-id-type="pmid">32338345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yousuf</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Alater</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alabdulla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>False Positive Tramadol Urine Testing in Patients Taking Fexofenadine: A Tale of Two Consecutive Cases.</article-title>
            <source>Case Rep Psychiatry</source>
            <year>2023</year>
            <volume>2023</volume>
            <fpage>4370648</fpage>
            <pub-id pub-id-type="pmid">36643013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Fexofenadine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31643886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pa&#x0015b;ko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodacki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Domaga&#x00142;a-Rodacka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palimonka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marcinkowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Owczarek</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Second generation H1 - antihistamines interaction with food and alcohol-A systematic review.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>93</volume>
            <fpage>27</fpage>
            <page-range>27-39</page-range>
            <pub-id pub-id-type="pmid">28622592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Estrada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Allergy Medications During Pregnancy.</article-title>
            <source>Am J Med Sci</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>352</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-31</page-range>
            <pub-id pub-id-type="pmid">27650241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Wegberg</surname>
                <given-names>AMJ</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahring</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x000e9;langer-Quintana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feillet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gi&#x0017c;ewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huijbregts</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leuzzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maillot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Muntau</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trefz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van Spronsen</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>The complete European guidelines on phenylketonuria: diagnosis and treatment.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <day>12</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <pub-id pub-id-type="pmid">29025426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratt</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahlbrandt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of fexofenadine HCl.</article-title>
            <source>Am J Cardiol</source>
            <year>1999</year>
            <month>May</month>
            <day>15</day>
            <volume>83</volume>
            <issue>10</issue>
            <fpage>1451</fpage>
            <page-range>1451-4</page-range>
            <pub-id pub-id-type="pmid">10335761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thi</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Thi</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Van</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Minh</surname>
                <given-names>PPT</given-names>
              </name>
              <name>
                <surname>Trong</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Van</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Huu</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Minh</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Huu</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Van</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Cam</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Huyen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hau</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Thanh</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Thi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Thuy</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Gandolfi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Satolli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feliciani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tirant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vojvodic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience.</article-title>
            <source>Open Access Maced J Med Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>30</day>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-263</page-range>
            <pub-id pub-id-type="pmid">30745975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuberbier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aberer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Asero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bindslev-Jensen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brzoza</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Ensina</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gim&#x000e9;nez-Arnau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grattan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdul Latiff</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Mathelier-Fusade</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmid-Grendelmeier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Staubach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Toubi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vena</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Wedi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <collab>European Academy of Allergy and Clinical Immunology</collab>
              <collab>Global Allergy and Asthma European Network</collab>
              <collab>European Dermatology Forum</collab>
              <collab>World Allergy Organization</collab>
            </person-group>
            <article-title>The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.</article-title>
            <source>Allergy</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>868</fpage>
            <page-range>868-87</page-range>
            <pub-id pub-id-type="pmid">24785199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paakkari</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity of new antihistamines and cisapride.</article-title>
            <source>Toxicol Lett</source>
            <year>2002</year>
            <month>Feb</month>
            <day>28</day>
            <volume>127</volume>
            <issue>1-3</issue>
            <fpage>279</fpage>
            <page-range>279-84</page-range>
            <pub-id pub-id-type="pmid">12052668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenwald</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Essner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Flomenbaum</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Increasing frequency and fatality of poison control center reported exposures involving medication and multiple substances: data from reports of the American Association of Poison Control Centers 1984-2013.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>590</fpage>
            <page-range>590-6</page-range>
            <pub-id pub-id-type="pmid">27214065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21720.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skypala</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Angier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kull</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Venter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vlieg-Boerstra</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Grimshaw</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Promoting and achieving excellence in the delivery of Integrated Allergy Care: the European Academy of Allergy &#x00026; Clinical Immunology competencies for allied health professionals working in allergy.</article-title>
            <source>Clin Transl Allergy</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">30151118</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
